Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19

Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19

Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interle...

Full description

Bibliographic Details
Main Authors: Steven Douedi, Moiuz Chaudhri, Jeffrey Miskoff
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Annals of Thoracic Medicine
Subjects:
covid-19
cytokine
interleukin-6
infection
monoclonal antibody
tocilizumab
Online Access:http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=3;spage=171;epage=173;aulast=Douedi

Internet

http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=3;spage=171;epage=173;aulast=Douedi

Similar Items